vs
Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $39.9M, roughly 1.9× COLONY BANKCORP INC). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 19.6%).
Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
CBAN vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $75.5M |
| Net Profit | $8.2M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 20.6% | — |
| Revenue YoY | — | 27.7% |
| Net Profit YoY | 24.1% | — |
| EPS (diluted) | — | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $75.5M | ||
| Q3 25 | $32.8M | $54.5M | ||
| Q2 25 | $32.5M | $52.4M | ||
| Q1 25 | $30.0M | $46.0M | ||
| Q4 24 | $30.8M | $59.1M | ||
| Q3 24 | $28.6M | $80.5M | ||
| Q2 24 | $27.9M | $47.1M |
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.8M | $8.8M | ||
| Q2 25 | $8.0M | $5.9M | ||
| Q1 25 | $6.6M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.6M | $20.3M | ||
| Q2 24 | $5.5M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | 22.7% | ||
| Q3 25 | 22.2% | 17.6% | ||
| Q2 25 | 30.9% | 12.7% | ||
| Q1 25 | 27.6% | 8.7% | ||
| Q4 24 | 28.8% | 22.6% | ||
| Q3 24 | 24.6% | 27.4% | ||
| Q2 24 | 24.8% | -4.6% |
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 17.7% | 16.2% | ||
| Q2 25 | 24.6% | 11.2% | ||
| Q1 25 | 22.0% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 19.7% | 25.2% | ||
| Q2 24 | 19.6% | -9.6% |
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $0.26 | ||
| Q3 25 | $0.33 | $0.17 | ||
| Q2 25 | $0.46 | $0.12 | ||
| Q1 25 | $0.38 | $0.06 | ||
| Q4 24 | $0.43 | $0.40 | ||
| Q3 24 | $0.32 | $0.41 | ||
| Q2 24 | $0.31 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $295.8M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $380.4M | $130.3M |
| Total Assets | $3.7B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $248.0M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $130.3M | ||
| Q3 25 | $302.3M | $115.3M | ||
| Q2 25 | $293.9M | $104.7M | ||
| Q1 25 | $286.9M | $97.1M | ||
| Q4 24 | $278.7M | $92.1M | ||
| Q3 24 | $276.1M | $71.1M | ||
| Q2 24 | $264.7M | $48.5M |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $216.3M | ||
| Q3 25 | $3.2B | $202.9M | ||
| Q2 25 | $3.1B | $194.9M | ||
| Q1 25 | $3.2B | $196.2M | ||
| Q4 24 | $3.1B | $213.3M | ||
| Q3 24 | $3.1B | $220.7M | ||
| Q2 24 | $3.0B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.89× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $14.4M | ||
| Q3 25 | $14.4M | $9.7M | ||
| Q2 25 | $15.8M | $14.1M | ||
| Q1 25 | $17.9M | $3.6M | ||
| Q4 24 | $23.4M | $15.6M | ||
| Q3 24 | $20.5M | $11.0M | ||
| Q2 24 | $1.1M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | $14.4M | ||
| Q3 25 | $14.1M | $9.7M | ||
| Q2 25 | $15.8M | $14.1M | ||
| Q1 25 | $17.6M | $3.6M | ||
| Q4 24 | $22.3M | $15.6M | ||
| Q3 24 | $20.2M | $11.0M | ||
| Q2 24 | $990.0K | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | 19.1% | ||
| Q3 25 | 42.9% | 17.7% | ||
| Q2 25 | 48.5% | 26.8% | ||
| Q1 25 | 58.7% | 7.7% | ||
| Q4 24 | 72.5% | 26.4% | ||
| Q3 24 | 70.6% | 13.7% | ||
| Q2 24 | 3.5% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | 3.5% | 0.0% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 0.5% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.48× | 1.10× | ||
| Q2 25 | 1.99× | 2.41× | ||
| Q1 25 | 2.71× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.64× | 0.54× | ||
| Q2 24 | 0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
PBYI
Segment breakdown not available.
